Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Industry
Pharmaceutical Preparations
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Leisure Acquisition Corp. (to 6/30/2021)
Latest financial report
10-K - Q4 2024 - Mar 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 272 % +126%
Debt-to-equity 49.4 % -77.7%
Operating Margin -129 % +73.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.41M shares -80.8%
Common Stock, Shares, Outstanding 1.36M shares +546%
Entity Public Float 4M USD -13%
Common Stock, Value, Issued 136 USD +548%
Weighted Average Number of Shares Outstanding, Basic 698K shares +362%
Weighted Average Number of Shares Outstanding, Diluted 698K shares +362%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 5.21M USD +134%
Research and Development Expense 7.22M USD -4.85%
General and Administrative Expense 4.72M USD -11.9%
Operating Income (Loss) -6.73M USD +37.2%
Nonoperating Income (Expense) -1.26M USD -1467%
Earnings Per Share, Basic -11.5 USD/shares +83.7%
Earnings Per Share, Diluted -11.5 USD/shares +83.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.5M USD +212%
Other Assets, Current 18K USD 0%
Assets, Current 5.34M USD +134%
Other Assets, Noncurrent 253K USD -39.8%
Assets 5.6M USD +107%
Accounts Payable, Current 1.36M USD -29.9%
Liabilities, Current 2.21M USD -33.8%
Other Liabilities, Noncurrent 10.1K USD -61.7%
Liabilities 2.22M USD -34%
Retained Earnings (Accumulated Deficit) -130M USD -6.57%
Stockholders' Equity Attributable to Parent 3.71M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.38M USD
Liabilities and Equity 5.6M USD +107%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.41M USD +5.5%
Net Cash Provided by (Used in) Financing Activities 5.69M USD +203%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 1.36M shares +546%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.28M USD
Deferred Tax Assets, Valuation Allowance 40.4M USD +5.04%
Deferred Tax Assets, Gross 40.4M USD +5.04%
Depreciation 0 USD
Operating Lease, Liability, Current 2.73K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.7M USD +4.36%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 1.83M USD +8.4%
Operating Lease, Payments 22.7K USD +18.9%
Additional Paid in Capital 133M USD +9.91%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 1.25M USD +83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%